A Progress Report

In keeping with the year-end synopsis focus of this special issue of Psychiatric Clinics of North America, this brief review focusses on key research discoveries and recent reports. Some discoveries advance our understanding of schizophrenia’s causation and others advance treatment approaches. Collectively, this synthesis should also convey to the discerning reader an overall sense of the state of play of translational research and clinical practice for schizophrenia. Although the neurobiology of mental illnesses in general—and in this instance schizophrenia—remains elusive, several recent studies point to some convergence in the genetics of schizophrenia. The collection and use of large collaborative databases have facilitated more detailed genetic inspections in schizophrenia. Two studies are illustrative. The Psychiatric Genomics Consortium conducted a large genomewide association study that found substantial overlap in risk loci between schizophrenia,

[1]  J. Lauriello,et al.  Comparison of SGA oral medications and a long-acting injectable SGA: the PROACTIVE study. , 2015, Schizophrenia bulletin.

[2]  H. Meltzer,et al.  A genetic locus in 7p12.2 associated with treatment resistant schizophrenia , 2014, Schizophrenia Research.

[3]  B. Nordestgaard,et al.  Elevated C-reactive protein associated with late- and very-late-onset schizophrenia in the general population: a prospective study. , 2014, Schizophrenia bulletin.

[4]  R. Rosenheck,et al.  Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial. , 2014, JAMA.

[5]  H. Meltzer,et al.  A six month randomized controlled trial of long acting injectable risperidone 50 and 100mg in treatment resistant schizophrenia , 2014, Schizophrenia Research.

[6]  P. Mortensen,et al.  Head injury as risk factor for psychiatric disorders: a nationwide register-based follow-up study of 113,906 persons with head injury. , 2014, The American journal of psychiatry.

[7]  F. Gage,et al.  Enhancing induced pluripotent stem cell models of schizophrenia. , 2014, JAMA psychiatry.

[8]  Godfrey Pearlson,et al.  Bipolar and schizophrenia network for intermediate phenotypes: outcomes across the psychosis continuum. , 2014, Schizophrenia bulletin.

[9]  P. Mortensen,et al.  A nationwide study on the risk of autoimmune diseases in individuals with a personal or a family history of schizophrenia and related psychosis. , 2014, The American journal of psychiatry.

[10]  E. Spina,et al.  Augmentation of Clozapine With Ziprasidone in Refractory Schizophrenia: A Double-Blind, Placebo-Controlled Study , 2014, Journal of clinical psychopharmacology.

[11]  B. Bogerts,et al.  Immune system and glucose metabolism interaction in schizophrenia: A chicken–egg dilemma , 2014, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[12]  Brian Kirkpatrick,et al.  Inflammation and schizophrenia. , 2013, Schizophrenia bulletin.

[13]  Patrick D McGorry,et al.  The next stage for diagnosis: validity through utility , 2013, World psychiatry : official journal of the World Psychiatric Association.

[14]  S. Heckers What is the core of schizophrenia? , 2013, JAMA psychiatry.

[15]  Dimitris Mavridis,et al.  Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis , 2013, The Lancet.

[16]  J. Lieberman,et al.  Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder. , 2013, The American journal of psychiatry.

[17]  Hok Pan Yuen,et al.  Long-term follow-up of a group at ultra high risk ("prodromal") for psychosis: the PACE 400 study. , 2013, JAMA psychiatry.

[18]  V. Carli,et al.  Childhood trauma and psychosis in a prospective cohort study: cause, effect, and directionality. , 2013, The American journal of psychiatry.

[19]  P. Fusar-Poli,et al.  Should attenuated psychosis syndrome be included in DSM-5? , 2012, The Lancet.

[20]  M. Cannon,et al.  Is traumatic brain injury a risk factor for schizophrenia? A meta-analysis of case-controlled population-based studies. , 2011, Schizophrenia bulletin.

[21]  W. Fleischhacker,et al.  Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial. , 2010, The international journal of neuropsychopharmacology.

[22]  R. Heinssen,et al.  Research domain criteria (RDoC): toward a new classification framework for research on mental disorders. , 2010, The American journal of psychiatry.

[23]  P. Buckley,et al.  First episode schizophrenia: Considerations on the timing, selection, and duration of antipsychotic therapies , 2009 .

[24]  Del D. Miller,et al.  Weight gain associated with the −759C/T polymorphism of the 5HT2C receptor and olanzapine , 2005, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[25]  E. Parellada,et al.  Increased susceptibility to apoptosis in cultured fibroblasts from antipsychotic-naïve first-episode schizophrenia patients. , 2014, Journal of psychiatric research.

[26]  A. Caspi,et al.  Neuropsychological decline in schizophrenia from the premorbid to the postonset period: evidence from a population-representative longitudinal study. , 2014, The American journal of psychiatry.

[27]  J. Lieberman,et al.  Apoptotic proteins in the temporal cortex in schizophrenia: high Bax/Bcl-2 ratio without caspase-3 activation. , 2004, The American journal of psychiatry.